Hemophilia A and B - Global Drug Forecast and Market Analysis to 2028

2019-08-31
Price :
Published : Aug-2019
No. of Pages : 228
Table of Contents
1.1 List of Tables
1.2 List of Figures
2 Executive Summary
2.1 Hemophilia A and B Market Expected to Grow to $9.3B by 2028
2.2 Inhibitor Segment Post-ACP Launch
2.3 ACPs and Gene Therapies to Radically Impact Hemophilia A and B Inhibitor and Non-Inhibitor Segments
2.4 Uncertainty in the Safety, Durability, and Availability of Gene Therapies Renders Curative Hemophilia Treatments a Continuing Unmet Need
2.5 Newcomers to Take Over Market Space from Established Companies
2.6 What Do Physicians Think?
3 Introduction
3.1 Catalyst
3.2 Related Reports
3.3 Upcoming Related Reports
4 Disease Overview
4.1 Etiology and Pathophysiology
4.1.1 Etiology
4.1.2 Pathophysiology
4.2 Classification
4.3 Symptoms
4.3.1 Hemophilia A and B
4.3.2 Inhibitors
4.4 Prognosis and Quality of Life
5 Epidemiology
5.1 Disease Background
5.2 Risk Factors and Comorbidities
5.3 Global and Historical Trends
5.4 Forecast Methodology
5.4.1 Sources
5.4.2 Forecast Assumptions and Methods
5.4.3 Diagnosed Prevalent Cases of Hemophilia A and Hemophilia B
5.4.4 Diagnosed Prevalent Cases of Hemophilia A and Hemophilia B by Severity
5.4.5 Diagnosed Prevalent Cases of Hemophilia A and Hemophilia B by Inhibitor Status
5.4.6 Severity Among Inhibitors in Diagnosed Prevalent Cases of Hemophilia A and Hemophilia B
5.4.7 Type of Treatment Among Diagnosed Prevalent Cases of Hemophilia A and Hemophilia B
5.4.8 Diagnosed Prevalent Cases of Acquired Hemophilia
5.5 Epidemiological Forecast for Hemophilia A (2018-2028)
5.5.1 Diagnosed Prevalent Cases of Hemophilia A
5.5.2 Age-Specific Diagnosed Prevalent Cases of Hemophilia A
5.5.3 Sex-Specific Diagnosed Prevalent Cases of Hemophilia A
5.5.4 Diagnosed Prevalent Cases of Hemophilia A by Severity
5.5.5 Diagnosed Prevalent Cases of Hemophilia A with Inhibitors
5.6 Epidemiological Forecast for Hemophilia B (2018-2028)
5.6.1 Diagnosed Prevalent Cases of Hemophilia B
5.6.2 Age-Specific Diagnosed Prevalent Cases of Hemophilia B
5.6.3 Sex-Specific Diagnosed Prevalent Cases of Hemophilia B
5.6.4 Diagnosed Prevalent Cases of Hemophilia B by Severity
5.6.5 Diagnosed Prevalent Cases of Hemophilia B with Inhibitors
5.7 Epidemiological Forecast for Hemophilia A and Hemophilia B (2018-2028)
5.7.1 Diagnosed Prevalent Cases of Hemophilia A and Hemophilia B
5.7.2 Age-Specific Diagnosed Prevalent Cases of Hemophilia A and Hemophilia B
5.7.3 Sex-Specific Diagnosed Prevalent Cases of Hemophilia A and Hemophilia B
5.7.4 Diagnosed Prevalent Cases of Hemophilia A and Hemophilia B by Severity
5.7.5 Diagnosed Prevalent Cases of Hemophilia A and Hemophilia B with Inhibitors
5.7.6 Severity Among Inhibitors in Diagnosed Prevalent Cases of Hemophilia A and Hemophilia B
5.7.7 Type of Treatment Among the Diagnosed Prevalent Cases of Hemophilia A and Hemophilia B
5.7.8 Diagnosed Prevalent Cases of Acquired Hemophilia
5.8 Discussion
5.8.1 Epidemiological Forecast Insight
5.8.2 Limitations of Analysis
5.8.3 Strengths of Analysis
6 Disease Management
6.1 Diagnosis and Treatment Overview
6.1.1 Treatment of Hemophilia A and B Without Inhibitors
6.1.2 Treatment of Hemophilia A and B Patients with Inhibitors
6.2 US
6.3 5EU
6.4 Japan
6.5 China
7 Competitive Assessment
7.1 Overview
7.2 Product Profiles - Hemophilia A
7.2.1 Short-Acting rFVIII
7.2.2 Long-Acting rFVIII
7.2.3 Alternative Coagulation Promoters
7.2.4 Plasma-Derived FVIII Concentrates
7.2.5 Desmopressin Acetate
7.3 Product Profiles - Hemophilia B
7.3.1 Short-Acting rFIX
7.3.2 Long-Acting rFIX
7.3.3 Plasma-Derived FIX Concentrates
7.4 Product Profiles - Hemophilia A and B with Inhibitors
8 Unmet Needs and Opportunities
8.1 Overview
8.2 Reduction in Risk of Inhibitor Development in Previously Untreated Patients
8.3 More Effective Treatments for Hemophilia B Patients with Inhibitors
8.4 More Therapies with Convenient Administration Routes
8.5 Treatments to Cure the Disease
8.6 Decreasing the Costs Associated with Prophylaxis and Promising Treatments
8.7 Individualized Prophylaxis
9 Pipeline Assessment
9.1 Overview
9.2 Promising Drugs in Clinical Development
9.3 Promising Approaches in Early-Stage Development
9.3.1 Alternative Coagulation Promoters - Tissue Factor Pathway Inhibitors
9.3.2 Gene Therapies
9.3.3 Replacement Strategies
9.3.4 Strategies to Prevent and Manage Inhibitors
10 Current and Future Players
10.1 Overview
10.2 Trends in Corporate Strategy
10.3 Company Profiles
10.3.1 Bayer
10.3.2 CSL Behring
10.3.3 Novo Nordisk
10.3.4 Pfizer
10.3.5 Roche
10.3.6 Sanofi
10.3.7 Takeda
11 Market Outlook
11.1 Global Markets
11.1.1 Forecast
11.1.2 Drivers and Barriers - Global Market
11.2 US
11.2.1 Forecast
11.2.2 Key Events
11.2.3 Drivers and Barriers
11.3 5EU
11.3.1 Forecast
11.3.2 Key Events
11.3.3 Drivers and Barriers - 5EU
11.4 Japan
11.4.1 Forecast
11.4.2 Key Events
11.4.3 Drivers and Barriers
11.5 China
11.5.1 Forecast
11.5.2 Key Events
11.5.3 Drivers and Barriers
12 Appendix

List of Tables
Table 1: Hemophilia A and B: Key Metrics in the Seven Major Markets, 2018-2028
Table 2: Relationship of Bleeding Severity with Clotting Factor Level.
Table 3: Comorbidities for Hemophilia
Table 4: 8MM Treatment Guidelines for Hemophilia
Table 5: The Most-Prescribed Hemophilia A and B Branded Drugs in the Global Markets, 2018
Table 6: Country Profile - US
Table 7: Country Profile - 5EU
Table 8: Country Profile - Japan
Table 9: Country Profile - China
Table 10: Leading Replacement Therapies for Hemophilia A and B and Patients with Inhibitors, 2019
Table 11: Marketed Plasma-Derived Replacement Therapies for Hemophilia A Patients, 2019
Table 12: Marketed Plasma-Derived Replacement Therapies for Hemophilia B Patients, 2019
Table 13: TFPI inhibitors - Early-Stage Pipeline, 2019
Table 14: Hemophilia A and B Gene Therapies - Early-Stage Pipeline, 2019
Table 15: Hemophilia A and B Recombinant Replacement Therapies - Early-Stage Pipeline, 2019
Table 16: Bayer's Hemophilia Portfolio Assessment, 2019
Table 17: CSL Behring's Hemophilia Recombinant Portfolio Assessment, 2019
Table 18: Novo Nordisk's Hemophilia Recombinant Portfolio Assessment, 2019
Table 19: Pfizer's Hemophilia Recombinant Portfolio Assessment, 2019
Table 20: Roche's Hemophilia Recombinant Portfolio Assessment, 2019
Table 21: Bioverativ/Sobi's Hemophilia Portfolio Assessment, 2019
Table 22: Takeda's Hemophilia Recombinant Portfolio Assessment, 2019
Table 23: Hemophilia A and B Market - Global Drivers and Barriers, 2018-2028
Table 24: Key Events Impacting Sales for Hemophilia A and B in the US, 2018-2028
Table 25: Hemophilia A and B Market - US Drivers and Barriers, 2018-2028
Table 26: Key Events Impacting Sales for Hemophilia A and B Therapeutics in the 5EU, 2018-2028
Table 27: Hemophilia A and B Market - 5EU Drivers and Barriers, 2018-2028
Table 28: Key Events Impacting Sales for Hemophilia A and B in Japan, 2018-2028
Table 29: Hemophilia A and B Market - Japan Drivers and Barriers, 2018-2028
Table 30: Key Events Impacting Sales for Hemophilia A and B in China, 2018-2028
Table 31: Hemophilia A and B Market - China Drivers and Barriers, 2018-2028
Table 32: Key Historical and Projected Launch Dates for Hemophilia A and B
Table 33: Key Historical and Projected Patent Expiry Dates for Hemophilia A and B
Table 34: Average Body Weight Across the 8MM
Table 35: Physicians Surveyed

List of Figures
Figure 1: Global Sales Forecast by Country for Hemophilia A and B, 2018-2028
Figure 2: Competitive Assessment of Late-Stage Pipeline Agents for Hemophilia A and B, 2018-2028
Figure 3: Key Company Portfolio Positioning in Hemophilia A and B, 2018-2028
Figure 4: 8MM, Diagnosed Prevalence of Hemophilia A (%), All Ages, 2018
Figure 5: 8MM, Diagnosed Prevalence of Hemophilia B (%), All Ages, 2018
Figure 6: 8MM, Sources Used, Diagnosed Prevalent Cases of Hemophilia A and Hemophilia B
Figure 7: 8MM, Sources Used, Diagnosed Prevalent Cases of Hemophilia A and Hemophilia B, by Severity
Figure 8: 8MM, Sources Used, Diagnosed Prevalent Cases of Hemophilia A and Hemophilia B with Inhibitors
Figure 9: 8MM, Sources Used, Severity Among Inhibitors in Diagnosed Prevalent Cases of Hemophilia A and Hemophilia B
Figure 10: 8MM, Sources Used, Type of Treatment Among Hemophilia A and Hemophilia B Patients
Figure 11: 8MM, Sources Used, Diagnosed Prevalent Cases of Acquired Hemophilia
Figure 12: 8MM, Diagnosed Prevalent Cases of Hemophilia A, All Ages, Both Sexes, N, 2018
Figure 13: 8MM, Age-Specific Diagnosed Prevalent Cases of Hemophilia A, Both Sexes, N, 2018
Figure 14: 8MM, Sex-Specific Diagnosed Prevalent Cases of Hemophilia A, All Ages, N, 2018
Figure 15: 8MM, Diagnosed Prevalent Cases of Hemophilia A by Severity, Both Sexes, All Ages, N, 2018
Figure 16: 8MM, Diagnosed Prevalent Cases of Hemophilia A with Inhibitors, Both Sexes, All Ages, N, 2018
Figure 17: 8MM, Diagnosed Prevalent Cases of Hemophilia B, All Ages, Both Sexes, 2018
Figure 18: 8MM, Age-Specific Diagnosed Prevalent Cases of Hemophilia B, Both Sexes, 2018
Figure 19: 8MM, Sex-Specific Diagnosed Prevalent Cases of Hemophilia B, All Ages, N, 2018
Figure 20: 8MM, Diagnosed Prevalent Cases of Hemophilia B by Severity, Both Sexes, All Ages, N, 2018
Figure 21: 8MM, Diagnosed Prevalent Cases of Hemophilia B with Inhibitors, Both Sexes, All Ages, N, 2018
Figure 22: 8MM, Diagnosed Prevalent Cases of Hemophilia A and Hemophilia B, Both Sexes, N, 2018
Figure 23: 8MM, Age-Specific Diagnosed Prevalent Cases of Hemophilia A and Hemophilia B, Both Sexes, N, 2018
Figure 24: 8MM, Sex-Specific Diagnosed Prevalent Cases of Hemophilia A and Hemophilia B, All Ages, N, 2018
Figure 25: 8MM, Diagnosed Prevalent Cases of Hemophilia A and Hemophilia B by Severity, Both Sexes, All Ages, N, 2018
Figure 26: 8MM, Diagnosed Prevalent Cases of Hemophilia A and Hemophilia B with Inhibitors, Both Sexes, All Ages, N, 2018
Figure 27: 8MM, Severity Among Inhibitors in Diagnosed Prevalent Cases of Hemophilia A and Hemophilia B, Both Sexes, All Ages, N, 2018
Figure 28: 8MM, Type of Treatment Among the Diagnosed Prevalent Cases of Hemophilia A and Hemophilia B, Both Sexes, All Ages, N, 2018
Figure 29: 8MM, Diagnosed Prevalent Cases of Acquired Hemophilia, All Ages, Both Sexes, N, 2018
Figure 30 : Flowchart of the Diagnosis and Management of Hemophilia Patients, With and Without Inhibitors
Figure 31: Unmet Needs and Opportunities in Hemophilia A and B
Figure 32: Competitive Assessment of Late-Stage Pipeline Agents, 2018-2028
Figure 33: Overview of the Development Pipeline in Hemophilia, 2018-2028
Figure 34: Hemophilia A and B - Phase III Pipeline, 2019
Figure 35: Company Portfolio Analysis in Hemophilia A and B, 2018-2028
Figure 36: Global Sales for Hemophilia A and B by Drug Class, 2018-2028
Figure 37: Global Sales Forecast by Country for Hemophilia A and B, 2018-2028
Figure 38: Global Sales Forecast by Patient Segment, 2018-2028
Figure 39: Sales for Hemophilia A and B Therapeutics in the US by Drug Class, 2018-2028
Figure 40: Sales for Hemophilia A and B Therapeutics in the 5EU by Drug Class, 2018-2028
Figure 41: Sales for Hemophilia A and B Therapeutics in Japan by Drug Class, 2018-2028
Figure 42: Sales for Hemophilia A and B Therapeutics in China by Drug Class, 2018-2028
Filed in: In Vitro Diagnostic, Medical Device
Publisher : GlobalData